Arsenic, Epigenetics and Incident Cardiovascular Disease in American Indians

美洲印第安人的砷、表观遗传学和心血管疾病事件

基本信息

  • 批准号:
    9087231
  • 负责人:
  • 金额:
    $ 35.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-06-15 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Inorganic arsenic in water and food are global health problems. Increasing epidemiologic and experimental evidence supports the role of low-moderate inorganic arsenic exposure as a cardiovascular disease (CVD) risk factor. In the Strong Heart Study (SHS), baseline urine arsenic concentrations were associated with incident CVD, supporting the need to investigate relevant mechanisms for arsenic related CVD, including epigenetic modifications. Objective: To investigate (1) if DNA epigenetic modifications mediate the association between arsenic and CVD and (2) if genetic variability modifies epigenetic mediation of arsenic related CVD in 3,574 SHS participants 45-74 years old and free of CVD at baseline. Preliminary studies: In a pilot study in the SHS, arsenic metabolism, measured by the relative proportion of arsenic species in urine, was associated with global DNA methylation and hydroxymethylation and arsenic exposure was associated with a hypomethylated region of AS3MT, the gene that codes a major methyltransferase involved in arsenic metabolism. In linkage and fine-mapping studies, genetic variants in the AS3MT region of the genome were associated with urine measures of arsenic metabolism. Design and setting: Population-based prospective cohort study of American Indian men and women from Arizona, Oklahoma and North/South Dakota recruited in 1989-1991 and followed through 2008 as part of the SHS. Data collection: Urine arsenic measures (reflecting long-term exposure), DNA samples to measure epigenetic modifications and genetic polymorphisms, CVD follow-up including coronary heart disease, stroke, peripheral artery disease and carotid plaque, and extensive data characterizing CVD and its risk factors are available. Epigenetic assessment: We will measure genome- wide blood DNA methylation at baseline using state-of-the-art high throughput technology to identify specific DNA methylation that may mediate the relationship between arsenic and incident CVD endpoints and validate the most promising regions using bisulfite pyrosequencing. Genetic assessment: We will measure 96 SNPs previously related to arsenic metabolism and toxicity in the Strong Heart Family Study, conducted in the same communities as the SHS. SNPs in candidate genes related to CVD are already available in the SHS. Statistical analysis: To evaluate if DNA epigenetic modifications mediate the association between arsenic and CVD, the following conditions will need to be met: (1) arsenic is associated with CVD (already confirmed), (2) arsenic is associated with DNA methylation, (3) DNA methylation is associated with CVD, conditional on arsenic exposure, and (4) attenuation of the arsenic-CVD association conditional on DNA methylation. Gene- epigene interactions will be assessed via general linear models and likelihood ratio tests. Significance: By investigating the contribution of arsenic epigenetics to CVD, this study can reveal novel mechanisms for arsenic health effects, identify susceptible populations, and inform risk assessment, with implications for the prevention and control of arsenic exposure in drinking water and food in the US and abroad.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

M Daniele Fallin其他文献

M Daniele Fallin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('M Daniele Fallin', 18)}}的其他基金

Study to Explore Early Development (SEED) Follow up Studies, Components A, B, D & E
探索早期发育的研究 (SEED) 后续研究,组成部分 A、B、D
  • 批准号:
    10299758
  • 财政年份:
    2021
  • 资助金额:
    $ 35.11万
  • 项目类别:
Study to Explore Early Development (SEED) Follow up Studies, Components A, B, D & E
探索早期发育的研究 (SEED) 后续研究,组成部分 A、B、D
  • 批准号:
    10408652
  • 财政年份:
    2021
  • 资助金额:
    $ 35.11万
  • 项目类别:
Expanding the Value of the EARLI study: Small Cohort with Big Data
扩大 EARLI 研究的价值:小队列与大数据
  • 批准号:
    10087931
  • 财政年份:
    2020
  • 资助金额:
    $ 35.11万
  • 项目类别:
HEALthy ORCHARD: Developing plans for a Baltimore site of the HEALthy BCD study
健康果园:为健康 BCD 研究巴尔的摩地点制定计划
  • 批准号:
    10021754
  • 财政年份:
    2019
  • 资助金额:
    $ 35.11万
  • 项目类别:
HEALthy ORCHARD: Developing plans for a Baltimore site of the HEALthy BCD study
健康果园:为健康 BCD 研究巴尔的摩地点制定计划
  • 批准号:
    9898784
  • 财政年份:
    2019
  • 资助金额:
    $ 35.11万
  • 项目类别:
Component A: MD CADDRE: Study to Explore Early Development, SEED Phase III
组件 A:MD CADDRE:探索早期开发的研究,SEED 第三阶段
  • 批准号:
    9310224
  • 财政年份:
    2016
  • 资助金额:
    $ 35.11万
  • 项目类别:
Component A: MD CADDRE: Study to Explore Early Development, SEED Phase III
组件 A:MD CADDRE:探索早期开发的研究,SEED 第三阶段
  • 批准号:
    9223273
  • 财政年份:
    2016
  • 资助金额:
    $ 35.11万
  • 项目类别:
Arsenic, Epigenetics and Incident Cardiovascular Disease in American Indians
美洲印第安人的砷、表观遗传学和心血管疾病事件
  • 批准号:
    8860791
  • 财政年份:
    2015
  • 资助金额:
    $ 35.11万
  • 项目类别:
Arsenic, Epigenetics and Incident Cardiovascular Disease in American Indians
美洲印第安人的砷、表观遗传学和心血管疾病事件
  • 批准号:
    9416700
  • 财政年份:
    2015
  • 资助金额:
    $ 35.11万
  • 项目类别:
MD CADDRE: Study to Explore Early Development, SEED Phase II
MD CADDRE:探索早期开发的研究,SEED 第二阶段
  • 批准号:
    8843568
  • 财政年份:
    2011
  • 资助金额:
    $ 35.11万
  • 项目类别:

相似海外基金

Communication in American Indians thru Strategies for Equity 4 Cancer (CASE4Cancer)
美国印第安人通过公平策略进行沟通 4 癌症 (CASE4Cancer)
  • 批准号:
    10892489
  • 财政年份:
    2023
  • 资助金额:
    $ 35.11万
  • 项目类别:
Digital smoking cessation intervention for nationally-recruited American Indians and Alaska Natives: A full-scale randomized controlled trial
针对全国招募的美洲印第安人和阿拉斯加原住民的数字戒烟干预:一项全面的随机对照试验
  • 批准号:
    10826067
  • 财政年份:
    2023
  • 资助金额:
    $ 35.11万
  • 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
  • 批准号:
    10419967
  • 财政年份:
    2022
  • 资助金额:
    $ 35.11万
  • 项目类别:
Examination of evolving opioid misuse and overdose risk among American Indians
检查美洲印第安人中不断变化的阿片类药物滥用和过量风险
  • 批准号:
    10438466
  • 财政年份:
    2022
  • 资助金额:
    $ 35.11万
  • 项目类别:
Examination of evolving opioid misuse and overdose risk among American Indians
检查美洲印第安人中不断变化的阿片类药物滥用和过量风险
  • 批准号:
    10701719
  • 财政年份:
    2022
  • 资助金额:
    $ 35.11万
  • 项目类别:
Culturally Responsive Palliative Care Messaging for American Indians: An Efficacy Trial
针对美洲印第安人的文化响应姑息治疗信息:功效试验
  • 批准号:
    10431092
  • 财政年份:
    2022
  • 资助金额:
    $ 35.11万
  • 项目类别:
Culturally Responsive Palliative Care Messaging for American Indians: An Efficacy Trial
针对美洲印第安人的文化响应姑息治疗信息:功效试验
  • 批准号:
    10709495
  • 财政年份:
    2022
  • 资助金额:
    $ 35.11万
  • 项目类别:
Advancing Palliative Care in Northern Plains American Indians
推进北部平原美洲印第安人的姑息治疗
  • 批准号:
    10705232
  • 财政年份:
    2022
  • 资助金额:
    $ 35.11万
  • 项目类别:
Long-term consequences of SARS-CoV-2 infection and COVID-19 disease among American Indians: an ambidirectional cohort study in the Cherokee Nation
美洲印第安人中 SARS-CoV-2 感染和 COVID-19 疾病的长期后果:切罗基族的双向队列研究
  • 批准号:
    10438443
  • 财政年份:
    2022
  • 资助金额:
    $ 35.11万
  • 项目类别:
Advancing Palliative Care in Northern Plains American Indians
推进北部平原美洲印第安人的姑息治疗
  • 批准号:
    10643600
  • 财政年份:
    2022
  • 资助金额:
    $ 35.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了